Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study

This pilot study investigated the safety and tolerability of daily oral supplementation with KGA-10. Study participants received a daily oral dose of 1 mg of this preparation. KGA-10 is a novel, environmentally-derived Mycolicibacterium petrae, which was heat-killed for the study and designated as NeuroAlly. The research compared the effects of this dietary supplement with a placebo consisting of microcrystalline cellulose. The primary objective was to evaluate the safety and tolerability of this substance in humans. The scientific study was sponsored and conducted by Kioga Inc. and the University of Colorado, Boulder. According to the provided information, this clinical study has already been completed.